Global Anti Peptic Ulcer Drugs Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Anti Peptic Ulcer Drugs Market Research Report 2024
Anti-peptic Ulcre drug is one of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract.
According to Mr Accuracy reports’s new survey, global Anti Peptic Ulcer Drugs market is projected to reach US$ 21380 million in 2034, increasing from US$ 8713 million in 2024, with the CAGR of 13.4% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Anti Peptic Ulcer Drugs market research.
Global Anti-Peptic Ulcer Drugs key players include AstraZeneca, Ask-pharm, Takeda, Yangtze River Pharm, Shandong Luoxin, etc. Global top five players hold a share about 50%.
In terms of product, the segment includes Proton Pump Inhibitors (PPIs), Potassium-Competitive Acid Blockers (P-CAB), Antacids, H2 Antagonists, Ulcer Protective Drugs. And in terms of application, the application includes Gastritis, Gastric Ulcers, Duodenal Ulcers, Gastroesophageal Reflux Disease (GERD).
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Anti Peptic Ulcer Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Eisai
Daewoong Pharmaceutical
Takeda Pharmaceutical
HeliCure
AstraZeneca
Ore Holdings
Sihuan Pharmaceutical
GlaxoSmithKline
Pfizer
Abbott Laboratories
Yuhan Corporation
Cadila Healthcare
Boehringer Ingelheim
Segment by Type
Proton Pump Inhibitors (PPIs)
Potassium-Competitive Acid Blockers (P-CAB)
Antacids
H2 Antagonists
Antibiotics
Ulcer Protective Drugs
Gastritis
Gastric Ulcers
Duodenal Ulcers
Gastroesophageal Reflux Disease (GERD)
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Anti Peptic Ulcer Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Anti Peptic Ulcer Drugs market is projected to reach US$ 21380 million in 2034, increasing from US$ 8713 million in 2024, with the CAGR of 13.4% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Anti Peptic Ulcer Drugs market research.
Global Anti-Peptic Ulcer Drugs key players include AstraZeneca, Ask-pharm, Takeda, Yangtze River Pharm, Shandong Luoxin, etc. Global top five players hold a share about 50%.
In terms of product, the segment includes Proton Pump Inhibitors (PPIs), Potassium-Competitive Acid Blockers (P-CAB), Antacids, H2 Antagonists, Ulcer Protective Drugs. And in terms of application, the application includes Gastritis, Gastric Ulcers, Duodenal Ulcers, Gastroesophageal Reflux Disease (GERD).
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Anti Peptic Ulcer Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Eisai
Daewoong Pharmaceutical
Takeda Pharmaceutical
HeliCure
AstraZeneca
Ore Holdings
Sihuan Pharmaceutical
GlaxoSmithKline
Pfizer
Abbott Laboratories
Yuhan Corporation
Cadila Healthcare
Boehringer Ingelheim
Segment by Type
Proton Pump Inhibitors (PPIs)
Potassium-Competitive Acid Blockers (P-CAB)
Antacids
H2 Antagonists
Antibiotics
Ulcer Protective Drugs
Segment by Application
Gastritis
Gastric Ulcers
Duodenal Ulcers
Gastroesophageal Reflux Disease (GERD)
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Anti Peptic Ulcer Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source